<VariationArchive VariationID="2946709" VariationName="NM_004168.4(SDHA):c.464del (p.Asn155fs)" VariationType="Deletion" Accession="VCV002946709" Version="3" RecordType="classified" NumberOfSubmissions="3" NumberOfSubmitters="3" DateLastUpdated="2024-07-29" DateCreated="2024-02-29" MostRecentSubmission="2024-05-01">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="3108369" VariationID="2946709">
      <GeneList>
        <Gene Symbol="SDHA" FullName="succinate dehydrogenase complex flavoprotein subunit A" GeneID="6389" HGNC_ID="HGNC:10680" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>5p15.33</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="5" Accession="NC_000005.10" start="218320" stop="268746" display_start="218320" display_stop="268746" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="5" Accession="NC_000005.9" start="218355" stop="256814" display_start="218355" display_stop="256814" Strand="+" />
          </Location>
          <OMIM>600857</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_004168.4(SDHA):c.464del (p.Asn155fs)</Name>
      <CanonicalSPDI>NC_000005.10:225886:AAAA:AAA</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>5p15.33</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="5" Accession="NC_000005.10" start="225887" stop="225887" display_start="225887" display_stop="225887" variantLength="1" positionVCF="225886" referenceAlleleVCF="GA" alternateAlleleVCF="G" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="5" Accession="NC_000005.9" start="226002" stop="226002" display_start="226002" display_stop="226002" variantLength="1" positionVCF="226001" referenceAlleleVCF="GA" alternateAlleleVCF="G" />
      </Location>
      <ProteinChange>N107fs</ProteinChange>
      <ProteinChange>N155fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000005.10" sequenceAccession="NC_000005" sequenceVersion="10" change="g.225890del" Assembly="GRCh38">
            <Expression>NC_000005.10:g.225890del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000005.9" sequenceAccession="NC_000005" sequenceVersion="9" change="g.226005del" Assembly="GRCh37">
            <Expression>NC_000005.9:g.226005del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_012339.1" sequenceAccession="NG_012339" sequenceVersion="1" change="g.12650del">
            <Expression>NG_012339.1:g.12650del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001294332.2" sequenceAccession="NM_001294332" sequenceVersion="2" change="c.320del">
            <Expression>NM_001294332.2:c.320del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001281261.1" sequenceAccession="NP_001281261" sequenceVersion="1" change="p.Asn107fs">
            <Expression>NP_001281261.1:p.Asn107fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001330758.2" sequenceAccession="NM_001330758" sequenceVersion="2" change="c.464del">
            <Expression>NM_001330758.2:c.464del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001317687.1" sequenceAccession="NP_001317687" sequenceVersion="1" change="p.Asn155fs">
            <Expression>NP_001317687.1:p.Asn155fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_004168.4" sequenceAccession="NM_004168" sequenceVersion="4" change="c.464del" MANESelect="true">
            <Expression>NM_004168.4:c.464del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_004159.2" sequenceAccession="NP_004159" sequenceVersion="2" change="p.Asn155fs">
            <Expression>NP_004159.2:p.Asn155fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_315" sequenceAccession="LRG_315">
            <Expression>LRG_315:g.12650del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_315t1" sequenceAccession="LRG_315t1">
            <Expression>LRG_315t1:c.464del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="LRG_315p1" sequenceAccession="LRG_315p1" change="p.Asn155fs">
            <Expression>LRG_315p1:p.Asn155fs</Expression>
          </ProteinExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_004168.3" sequenceAccession="NM_004168" sequenceVersion="3" change="c.464delA">
            <Expression>NM_004168.3:c.464delA</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_004168.4(SDHA):c.464del (p.Asn155fs) AND multiple conditions" Accession="RCV003808947" Version="1">
        <ClassifiedConditionList TraitSetID="23694">
          <ClassifiedCondition DB="MedGen" ID="C5700310">Mitochondrial complex II deficiency, nuclear type 1</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C3279992">Paragangliomas 5</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-04-14" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_004168.4(SDHA):c.464del (p.Asn155fs) AND Paragangliomas 5" Accession="RCV004366652" Version="1">
        <ClassifiedConditionList TraitSetID="7580">
          <ClassifiedCondition DB="MedGen" ID="C3279992">Paragangliomas 5</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2024-02-21" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_004168.4(SDHA):c.464del (p.Asn155fs) AND SDHA-related disorder" Accession="RCV004542276" Version="1">
        <ClassifiedConditionList TraitSetID="47324">
          <ClassifiedCondition>SDHA-related disorder</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-11-15" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2024-02-21" NumberOfSubmissions="3" NumberOfSubmitters="3" DateCreated="2024-02-29" MostRecentSubmission="2024-05-01">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">22974104</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">24781757</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="47324" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="41751" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">SDHA-related condition</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">SDHA-related disorder</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">SDHA-Related Disorders</ElementValue>
              </Name>
            </Trait>
          </TraitSet>
          <TraitSet ID="23694" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="16481" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Paragangliomas 5</ElementValue>
                <XRef ID="Paragangliomas+5/9075" DB="Genetic Alliance" />
                <XRef ID="MONDO:0013602" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">PHEOCHROMOCYTOMA/PARAGANGLIOMA SYNDROME 5</ElementValue>
                <XRef Type="MIM" ID="614165" DB="OMIM" />
                <XRef Type="Allelic variant" ID="600857.0005" DB="OMIM" />
                <XRef Type="Allelic variant" ID="600857.0009" DB="OMIM" />
                <XRef Type="Allelic variant" ID="600857.0010" DB="OMIM" />
                <XRef Type="Allelic variant" ID="600857.0008" DB="OMIM" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">PPGL5</ElementValue>
                <XRef Type="MIM" ID="614165" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">PGL5</ElementValue>
                <XRef Type="MIM" ID="614165" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Hereditary paraganglioma-pheochromocytoma (PGL/PCC) syndromes are characterized by paragangliomas (tumors that arise from neuroendocrine tissues distributed along the paravertebral axis from the base of the skull to the pelvis) and pheochromocytomas (paragangliomas that are confined to the adrenal medulla). Sympathetic paragangliomas cause catecholamine excess; parasympathetic paragangliomas are most often nonsecretory. Extra-adrenal parasympathetic paragangliomas are located predominantly in the skull base and neck (referred to as head and neck PGL [HNPGL]) and sometimes in the upper mediastinum; approximately 95% of such tumors are nonsecretory. In contrast, sympathetic extra-adrenal paragangliomas are generally confined to the lower mediastinum, abdomen, and pelvis, and are typically secretory. Pheochromocytomas, which arise from the adrenal medulla, typically lead to catecholamine excess. Symptoms of PGL/PCC result from either mass effects or catecholamine hypersecretion (e.g., sustained or paroxysmal elevations in blood pressure, headache, episodic profuse sweating, forceful palpitations, pallor, and apprehension or anxiety). The risk for developing metastatic disease is greater for extra-adrenal sympathetic paragangliomas than for pheochromocytomas.</Attribute>
                <XRef ID="NBK1548" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="15763" />
                <XRef ID="15763" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301715</ID>
                <ID Source="BookShelf">NBK1548</ID>
              </Citation>
              <Citation Type="general" Abbrev="ES, 2014">
                <ID Source="PubMed">24893135</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2023">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Neuroendocrine and Adrenal Tumors, 2023</CitationText>
              </Citation>
              <XRef ID="29072" DB="Orphanet" />
              <XRef ID="C3279992" DB="MedGen" />
              <XRef ID="MONDO:0013602" DB="MONDO" />
              <XRef Type="MIM" ID="614165" DB="OMIM" />
            </Trait>
            <Trait ID="5546" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Mitochondrial complex II deficiency, nuclear type 1</ElementValue>
                <XRef ID="MONDO:0100294" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Mitochondrial complex II deficiency</ElementValue>
                <XRef ID="Mitochondrial+complex+II+deficiency/4824" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Complex 2 mitochondrial respiratory chain deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Succinate CoQ reductase deficiency</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="5053" />
                <XRef ID="5053" DB="Office of Rare Diseases" />
              </AttributeSet>
              <XRef ID="3208" DB="Orphanet" />
              <XRef ID="C5700310" DB="MedGen" />
              <XRef ID="MONDO:0100294" DB="MONDO" />
              <XRef Type="MIM" ID="252011" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="7580" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="16481" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Paragangliomas 5</ElementValue>
                <XRef ID="Paragangliomas+5/9075" DB="Genetic Alliance" />
                <XRef ID="MONDO:0013602" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">PHEOCHROMOCYTOMA/PARAGANGLIOMA SYNDROME 5</ElementValue>
                <XRef Type="MIM" ID="614165" DB="OMIM" />
                <XRef Type="Allelic variant" ID="600857.0005" DB="OMIM" />
                <XRef Type="Allelic variant" ID="600857.0009" DB="OMIM" />
                <XRef Type="Allelic variant" ID="600857.0010" DB="OMIM" />
                <XRef Type="Allelic variant" ID="600857.0008" DB="OMIM" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">PPGL5</ElementValue>
                <XRef Type="MIM" ID="614165" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">PGL5</ElementValue>
                <XRef Type="MIM" ID="614165" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Hereditary paraganglioma-pheochromocytoma (PGL/PCC) syndromes are characterized by paragangliomas (tumors that arise from neuroendocrine tissues distributed along the paravertebral axis from the base of the skull to the pelvis) and pheochromocytomas (paragangliomas that are confined to the adrenal medulla). Sympathetic paragangliomas cause catecholamine excess; parasympathetic paragangliomas are most often nonsecretory. Extra-adrenal parasympathetic paragangliomas are located predominantly in the skull base and neck (referred to as head and neck PGL [HNPGL]) and sometimes in the upper mediastinum; approximately 95% of such tumors are nonsecretory. In contrast, sympathetic extra-adrenal paragangliomas are generally confined to the lower mediastinum, abdomen, and pelvis, and are typically secretory. Pheochromocytomas, which arise from the adrenal medulla, typically lead to catecholamine excess. Symptoms of PGL/PCC result from either mass effects or catecholamine hypersecretion (e.g., sustained or paroxysmal elevations in blood pressure, headache, episodic profuse sweating, forceful palpitations, pallor, and apprehension or anxiety). The risk for developing metastatic disease is greater for extra-adrenal sympathetic paragangliomas than for pheochromocytomas.</Attribute>
                <XRef ID="NBK1548" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="15763" />
                <XRef ID="15763" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301715</ID>
                <ID Source="BookShelf">NBK1548</ID>
              </Citation>
              <Citation Type="general" Abbrev="ES, 2014">
                <ID Source="PubMed">24893135</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2023">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Neuroendocrine and Adrenal Tumors, 2023</CitationText>
              </Citation>
              <XRef ID="29072" DB="Orphanet" />
              <XRef ID="C3279992" DB="MedGen" />
              <XRef ID="MONDO:0013602" DB="MONDO" />
              <XRef Type="MIM" ID="614165" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="8550027" SubmissionDate="2024-02-15" DateLastUpdated="2024-02-28" DateCreated="2024-02-28">
        <ClinVarSubmissionID localKey="21175750|MedGen:C3279992;C1855008" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004596574" DateUpdated="2024-02-28" DateCreated="2024-02-28" Type="SCV" Version="1" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-04-14">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">22974104</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">24781757</ID>
          </Citation>
          <Comment>Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. For these reasons, this variant has been classified as Pathogenic. This variant has not been reported in the literature in individuals affected with SDHA-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Asn155Ilefs*71) in the SDHA gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in SDHA are known to be pathogenic (PMID: 22974104, 24781757).</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SDHA" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000005.9:g.226002del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease" multipleConditionExplanation="Uncertain">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C3279992" Type="CUI" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C1855008" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB14224806</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="8864488" SubmissionDate="2024-03-08" DateLastUpdated="2024-03-16" DateCreated="2024-03-16">
        <ClinVarSubmissionID localKey="38706669|SDHA-related condition" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004780154" DateUpdated="2024-03-16" DateCreated="2024-03-16" Type="SCV" Version="1" SubmitterName="PreventionGenetics, part of Exact Sciences" OrgID="239772" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-11-15">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>The SDHA c.464delA variant is predicted to result in a frameshift and premature protein termination (p.Asn155Ilefs*71). To our knowledge, this variant has not been reported in the literature or in a large population database (http://gnomad.broadinstitute.org), indicating this variant is rare. Frameshift variants in SDHA are expected to be pathogenic. This variant is interpreted as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SDHA" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_004168.3:c.464delA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">SDHA-related condition</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB14299258</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="9142751" SubmissionDate="2024-04-22" DateLastUpdated="2024-05-01" DateCreated="2024-05-01">
        <ClinVarSubmissionID localKey="102512338|OMIM:614165" />
        <ClinVarAccession Accession="SCV004930939" DateUpdated="2024-05-01" DateCreated="2024-05-01" Type="SCV" Version="1" SubmitterName="Myriad Genetics, Inc." OrgID="507240" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2024-02-21">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>This variant is considered pathogenic. This variant creates a frameshift predicted to result in premature protein truncation.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Myriad Autosomal Dominant, Autosomal Recessive and X-Linked Classification Criteria (2023)</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/8ufcwsf2/myriad_genetics_classification_criteria_2023.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SDHA" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <SequenceLocation Assembly="hg19" Chr="5" alternateAllele="A" referenceAllele="AA" start="226004" stop="226005" />
          </Location>
          <OtherNameList>
            <Name Type="SubmitterVariantId">102512338</Name>
          </OtherNameList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="614165" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB14395420</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="9142751" TraitType="Disease" MappingType="XRef" MappingValue="614165" MappingRef="OMIM">
        <MedGen CUI="C3279992" Name="Paragangliomas 5" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="8864488" TraitType="Disease" MappingType="Name" MappingValue="SDHA-related condition" MappingRef="Preferred">
        <MedGen CUI="None" Name="SDHA-related disorder" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="8550027" TraitType="Disease" MappingType="XRef" MappingValue="C1855008" MappingRef="MedGen">
        <MedGen CUI="C5700310" Name="Mitochondrial complex II deficiency, nuclear type 1" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="8550027" TraitType="Disease" MappingType="XRef" MappingValue="C3279992" MappingRef="MedGen">
        <MedGen CUI="C3279992" Name="Paragangliomas 5" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

